RemeGen (HKG:9995, SHA:688331) reported a net loss attributable to shareholders of 291.0 million yuan for the quarter ended Sept. 30, according to a Tuesday filing with the Hong Kong bourse.
The loss per share for the quarter was 0.54 yuan.
Revenue was 467.1 million yuan, a 34.60% increase from the prior-year quarter.
Hong Kong shares of the biopharmaceutical company gained 3% in morning trade Wednesday, while its Shanghai shares gained nearly 4%.